CGRP antagonists for decreasing migraine frequency: New options, long overdue

被引：6

作者：

Bucklan, Julia ^{[1
,2
]}

Ahmed, Zubair ^{[2
,3
]}

机构：

[1] Cleveland Clin, Dept Neurol, Ctr Gen Neurol, Cleveland, OH 44195 USA

[2] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA

[3] Cleveland Clin, Dept Neurol, Ctr Neurorestorat, Cleveland, OH 44195 USA

来源：

CLEVELAND CLINIC JOURNAL OF MEDICINE | 2020年 / 87卷 / 04期

关键词：

PREVENTIVE TREATMENT; EPISODIC MIGRAINE; CONTROLLED-TRIAL; DOUBLE-BLIND; MEDICATION OVERUSE; HEADACHE; ERENUMAB; FREMANEZUMAB; PATHOPHYSIOLOGY; NEUROPEPTIDE;

D O I：

10.3949/ccjm.87a.19048

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The cornerstone of preventive migraine treatment has long been drugs developed for other diseases such as epilepsy, depression, and hypertension. But a new set of drugs is available for preventing migraine attacks: erenumab, galcanezumab, fremanezumab, and eptinezumab. These monoclonal antibodies target calcitonin gene-related peptide (CGRP) or its receptors, each a key molecule in the pathophysiology of migraine.

引用

页码：211 / 218

页数：8

共 53 条

[1]

[Anonymous], 2018, NEUROLOGY

[2]

Becker WJ, 2015, CAN FAM PHYSICIAN, V61, P670

[3]

Benarroch EE, 2011, NEUROLOGY, V77, P281, DOI [10.1212/WNL.0b013e31822550e2, 10.1212/WNL.0b013e3182074c2f]

[4] TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points [J].